- Home
- AIRT vs ZURA Comparison
AIRT vs ZURA Comparison
Compare AIRT & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- ZURA
- Stock Information
- Founded
- AIRT 1980
- ZURA 2022
- Country
- AIRT United States
- ZURA United States
- Employees
- AIRT N/A
- ZURA N/A
- Industry
- AIRT Air Freight/Delivery Services
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AIRT Consumer Discretionary
- ZURA Health Care
- Exchange
- AIRT Nasdaq
- ZURA Nasdaq
- Market Cap
- AIRT 59.6M
- ZURA 69.9M
- IPO Year
- AIRT N/A
- ZURA N/A
- Fundamental
- Price
- AIRT $24.46
- ZURA $1.90
- Analyst Decision
- AIRT
- ZURA Buy
- Analyst Count
- AIRT 0
- ZURA 10
- Target Price
- AIRT N/A
- ZURA $12.67
- AVG Volume (30 Days)
- AIRT 1.2K
- ZURA 292.6K
- Earning Date
- AIRT 11-11-2025
- ZURA 11-06-2025
- Dividend Yield
- AIRT N/A
- ZURA N/A
- EPS Growth
- AIRT N/A
- ZURA N/A
- EPS
- AIRT N/A
- ZURA N/A
- Revenue
- AIRT $296,309,000.00
- ZURA N/A
- Revenue This Year
- AIRT N/A
- ZURA N/A
- Revenue Next Year
- AIRT N/A
- ZURA N/A
- P/E Ratio
- AIRT N/A
- ZURA N/A
- Revenue Growth
- AIRT 5.14
- ZURA N/A
- 52 Week Low
- AIRT $14.56
- ZURA $0.97
- 52 Week High
- AIRT $26.70
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- AIRT 55.22
- ZURA 48.83
- Support Level
- AIRT $22.63
- ZURA $1.88
- Resistance Level
- AIRT $26.37
- ZURA $2.19
- Average True Range (ATR)
- AIRT 0.33
- ZURA 0.14
- MACD
- AIRT 0.12
- ZURA -0.04
- Stochastic Oscillator
- AIRT 53.53
- ZURA 5.00
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.